Safety goes (Re)Viral

Strong safety data prompted Novo to co-lead ReViral’s $55M series B

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners.

The round closed Wednesday and

Read the full 380 word article

User Sign In